Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090
NCT04015180
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Retinopathy of Prematurity (ROP)
Interventions
DRUG:
Eylea (Aflibercept, BAY86-5321)
PROCEDURE:
Laser photocoagulation
Sponsor
Bayer
Collaborators
[object Object]